Over the past 12 months, $BBIO was mentioned 13 times across 3 distinct FinTwit voices, with @adamfeuerstein accounting for all 13 mentions. The first mention appeared on 2025-09-11, and discussions continued through 2026-07-06. As a biotech-focused ticker, $BBIO appeared primarily in conversations about transthyretin amyloid cardiomyopathy (ATTR-CM) drug development and competitive dynamics in the space. The most recent mentions centered on competitive positioning following clinical trial outcomes in the ATTR-CM market.